急性淋巴细胞白血病患儿甲氨蝶呤抢救治疗中亚叶酸钙与碳酸氢盐的物理相容性评估策略。

IF 5.5 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Kaveh Teimori, Bjarke Strøm Larsen, Mathias Buaas Austli, Niklas Nilsson, Ingunn Tho, Katerina Nezvalova-Henriksen
{"title":"急性淋巴细胞白血病患儿甲氨蝶呤抢救治疗中亚叶酸钙与碳酸氢盐的物理相容性评估策略。","authors":"Kaveh Teimori, Bjarke Strøm Larsen, Mathias Buaas Austli, Niklas Nilsson, Ingunn Tho, Katerina Nezvalova-Henriksen","doi":"10.3390/pharmaceutics17091155","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives</b>: Acute lymphoblastic leukemia (ALL) is the most prevalent childhood cancer requiring cytotoxic methotrexate treatment. This always necessitates intravenous administration of rescue therapy consisting of calcium folinate and bicarbonate. Current recommendations advise against mixing these two drugs due to concerns regarding precipitate formation of calcium carbonate (CaCO<sub>3</sub>) that could result in catheter and capillary obstruction. These recommendations are based on drug concentrations not clinically relevant in pediatric ALL settings. Our study investigated the effect of clinically relevant calcium folinate-bicarbonate concentrations on the risk of CaCO<sub>3</sub> precipitation. <b>Methods</b>: A theoretical prediction model provided estimates of final mixing concentrations in five scenarios: three simulated pediatric patient models (approx. 1, 9, and 14 years), an undiluted drug mix, and a high-risk control outlier case. Physical compatibility tests were conducted using validated methods for particle detection, complemented by Raman spectroscopy for particle identification. <b>Results</b>: Theoretical predictions suggested CaCO<sub>3</sub> precipitation with elevated bicarbonate concentrations and pH levels. Our simulated patient models and high-risk control outlier case showed that CaCO<sub>3</sub> precipitation may be avoided below certain serum methotrexate concentrations and thereby calcium folinate and bicarbonate concentrations. Physical testing demonstrated particle formation only in the undiluted mix with Raman spectroscopy confirming the finding. <b>Conclusions</b>: Mixing calcium folinate and bicarbonate appears safe under specific methotrexate-directed pediatric ALL treatment conditions. While high bicarbonate concentrations pose precipitation risks, protocol-based dosing regimens mitigate this. Switching to disodium folinate or using in-line filters could further enhance co-administration safety if bicarbonate concentrations exceed the safety limit suggested by our results.</p>","PeriodicalId":19894,"journal":{"name":"Pharmaceutics","volume":"17 9","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472967/pdf/","citationCount":"0","resultStr":"{\"title\":\"Strategies for Assessing Physical Compatibility of Calcium Folinate with Bicarbonate During Methotrexate Rescue Therapy in Pediatric Patients with Acute Lymphoblastic Leukemia.\",\"authors\":\"Kaveh Teimori, Bjarke Strøm Larsen, Mathias Buaas Austli, Niklas Nilsson, Ingunn Tho, Katerina Nezvalova-Henriksen\",\"doi\":\"10.3390/pharmaceutics17091155\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background/Objectives</b>: Acute lymphoblastic leukemia (ALL) is the most prevalent childhood cancer requiring cytotoxic methotrexate treatment. This always necessitates intravenous administration of rescue therapy consisting of calcium folinate and bicarbonate. Current recommendations advise against mixing these two drugs due to concerns regarding precipitate formation of calcium carbonate (CaCO<sub>3</sub>) that could result in catheter and capillary obstruction. These recommendations are based on drug concentrations not clinically relevant in pediatric ALL settings. Our study investigated the effect of clinically relevant calcium folinate-bicarbonate concentrations on the risk of CaCO<sub>3</sub> precipitation. <b>Methods</b>: A theoretical prediction model provided estimates of final mixing concentrations in five scenarios: three simulated pediatric patient models (approx. 1, 9, and 14 years), an undiluted drug mix, and a high-risk control outlier case. Physical compatibility tests were conducted using validated methods for particle detection, complemented by Raman spectroscopy for particle identification. <b>Results</b>: Theoretical predictions suggested CaCO<sub>3</sub> precipitation with elevated bicarbonate concentrations and pH levels. Our simulated patient models and high-risk control outlier case showed that CaCO<sub>3</sub> precipitation may be avoided below certain serum methotrexate concentrations and thereby calcium folinate and bicarbonate concentrations. Physical testing demonstrated particle formation only in the undiluted mix with Raman spectroscopy confirming the finding. <b>Conclusions</b>: Mixing calcium folinate and bicarbonate appears safe under specific methotrexate-directed pediatric ALL treatment conditions. While high bicarbonate concentrations pose precipitation risks, protocol-based dosing regimens mitigate this. Switching to disodium folinate or using in-line filters could further enhance co-administration safety if bicarbonate concentrations exceed the safety limit suggested by our results.</p>\",\"PeriodicalId\":19894,\"journal\":{\"name\":\"Pharmaceutics\",\"volume\":\"17 9\",\"pages\":\"\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472967/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/pharmaceutics17091155\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pharmaceutics17091155","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:急性淋巴细胞白血病(ALL)是最常见的儿童癌症,需要细胞毒性甲氨蝶呤治疗。这总是需要静脉注射由亚叶酸钙和碳酸氢盐组成的抢救治疗。目前的建议不建议将这两种药物混合使用,因为碳酸钙(CaCO3)的沉淀形成可能导致导管和毛细血管阻塞。这些建议是基于与儿科ALL环境无临床相关性的药物浓度。我们的研究调查了临床相关的亚叶酸钙-碳酸氢盐浓度对CaCO3沉淀风险的影响。方法:理论预测模型提供了五种情况下的最终混合浓度估计值:三种模拟儿科患者模型(大约;1、9和14岁),未稀释的药物混合物,以及高危对照异常病例。物理相容性测试采用经过验证的粒子检测方法进行,并辅以拉曼光谱进行粒子识别。结果:理论预测表明碳酸氢盐浓度和pH值升高导致碳酸氢盐沉淀。我们的模拟患者模型和高危对照异常病例表明,在一定的血清甲氨蝶呤浓度下,可以避免CaCO3沉淀,从而避免亚叶酸钙和碳酸氢盐浓度。物理测试表明,只有在未稀释的混合物中才会形成颗粒,拉曼光谱证实了这一发现。结论:在甲氨蝶呤导向的儿科ALL治疗条件下,混合亚叶酸钙和碳酸氢盐是安全的。虽然高浓度碳酸氢盐会带来降水风险,但基于方案的给药方案可以减轻这种风险。如果碳酸氢盐浓度超过我们的研究结果所建议的安全限度,切换到亚叶酸二钠或使用在线过滤器可以进一步提高联合给药的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Strategies for Assessing Physical Compatibility of Calcium Folinate with Bicarbonate During Methotrexate Rescue Therapy in Pediatric Patients with Acute Lymphoblastic Leukemia.

Strategies for Assessing Physical Compatibility of Calcium Folinate with Bicarbonate During Methotrexate Rescue Therapy in Pediatric Patients with Acute Lymphoblastic Leukemia.

Strategies for Assessing Physical Compatibility of Calcium Folinate with Bicarbonate During Methotrexate Rescue Therapy in Pediatric Patients with Acute Lymphoblastic Leukemia.

Strategies for Assessing Physical Compatibility of Calcium Folinate with Bicarbonate During Methotrexate Rescue Therapy in Pediatric Patients with Acute Lymphoblastic Leukemia.

Background/Objectives: Acute lymphoblastic leukemia (ALL) is the most prevalent childhood cancer requiring cytotoxic methotrexate treatment. This always necessitates intravenous administration of rescue therapy consisting of calcium folinate and bicarbonate. Current recommendations advise against mixing these two drugs due to concerns regarding precipitate formation of calcium carbonate (CaCO3) that could result in catheter and capillary obstruction. These recommendations are based on drug concentrations not clinically relevant in pediatric ALL settings. Our study investigated the effect of clinically relevant calcium folinate-bicarbonate concentrations on the risk of CaCO3 precipitation. Methods: A theoretical prediction model provided estimates of final mixing concentrations in five scenarios: three simulated pediatric patient models (approx. 1, 9, and 14 years), an undiluted drug mix, and a high-risk control outlier case. Physical compatibility tests were conducted using validated methods for particle detection, complemented by Raman spectroscopy for particle identification. Results: Theoretical predictions suggested CaCO3 precipitation with elevated bicarbonate concentrations and pH levels. Our simulated patient models and high-risk control outlier case showed that CaCO3 precipitation may be avoided below certain serum methotrexate concentrations and thereby calcium folinate and bicarbonate concentrations. Physical testing demonstrated particle formation only in the undiluted mix with Raman spectroscopy confirming the finding. Conclusions: Mixing calcium folinate and bicarbonate appears safe under specific methotrexate-directed pediatric ALL treatment conditions. While high bicarbonate concentrations pose precipitation risks, protocol-based dosing regimens mitigate this. Switching to disodium folinate or using in-line filters could further enhance co-administration safety if bicarbonate concentrations exceed the safety limit suggested by our results.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmaceutics
Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
7.90
自引率
11.10%
发文量
2379
审稿时长
16.41 days
期刊介绍: Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications,  and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation. Our aim is to encourage scientists to publish their experimental and theoretical details in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信